A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Trials Related to Metastatic Melanoma
Related studies linked through entity extraction aliases.
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes
- Status
- TERMINATED
- Phase
- EARLY_PHASE1
TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)
- Status
- COMPLETED
- Phase
- PHASE1
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
- Status
- TERMINATED
- Phase
- PHASE3
A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE3
Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma
- Status
- TERMINATED
- Phase
- PHASE1
A Study of ASN007 in Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors
- Status
- COMPLETED
- Phase
- N/A
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
A Study of ADXS-NEO Expressing Personalized Tumor Antigens
- Status
- TERMINATED
- Phase
- PHASE1
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic Melanoma
- Status
- COMPLETED
- Phase
- NA
Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors
- Status
- COMPLETED
- Phase
- NA
Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Tolerance of Targeted Therapy Used in Metastatic Melanoma in Patients Aged Over 65 and 75-year-old
- Status
- COMPLETED
- Phase
- N/A
Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2